GlassScriptPhysician profile
Courtney Wolf
NPI 1275251233
$4,597.44
in general payments reported to CMS, 2019-2025
21 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $355 · 2023: $1,680 · 2024: $1,380 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,291.79 | 2022-2025 | |
| Genzyme Corporation | $646.20 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $597.86 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $338.47 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $301.43 | 2022-2025 | Tremfya |
| Amgen INC. | $301.28 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $212.77 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $144.70 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $115.17 | 2022-2025 | Opzelura |
| Pfizer INC. | $114.34 | 2022-2023 | |
| Ucb, INC. | $95.29 | 2023-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.83 | 2022-2023 | Cyltezo, Spevigo |
| Dermavant Sciences, INC. | $83.08 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $63.68 | 2024 | |
| Galderma Laboratories, L.P. | $46.70 | 2024-2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $42.89 | 2025 | Sofdra |
| Chiesi USA, INC. | $29.57 | 2025 | Filsuvez |
| Fresenius Kabi USA, LLC | $28.77 | 2024 | Idacio |
| Blueprint Medicines Corporation | $23.96 | 2025 | Ayvakit |
| Smith+Nephew, INC. | $20.75 | 2025 | Collagenase Santyl |
| Arcutis Biotherapeutics, INC. | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.